Articles tagged with Molecular Imaging
Researchers at MIT have developed an alternative method to study molecular signals in cells, allowing them to track up to seven different molecules simultaneously. The technique uses fluorescent proteins that flicker on and off at different rates, enabling the tracking of specific cellular functions over time.
Researchers have developed a novel PET radiotracer that enables early detection of inflammatory bowel disease (IBD) with high spatial and molecular specificity. The imaging tool targets the IBD biomarker IL12/23p40, providing detailed information for accurate diagnosis and treatment.
Scientists develop antiaromatic molecules that exhibit absorption and fluorescence bands in the near-infrared region, enabling deep biological imaging and photothermal therapy. This breakthrough holds potential for diverse NIR luminescent materials and applications in fields like healthcare, optoelectronics, and materials science.
A study found that bone scans overstage prostate cancer at initial staging, leading to potential withholding of definitive therapy from patients. PSMA PET is more accurate than CT and bone scans for staging patients with prostate cancer.
A team of researchers has developed a novel experimental system to simultaneously measure the mechanical properties and internal structure of rubber-like materials. The study found that strain within these materials is non-uniform, depending on the shape and size of composite particles.
Regular cannabis users show a greater understanding of others' emotions, while their brains exhibit stronger connections between regions related to emotional sensing. This study suggests potential therapeutic applications for conditions involving social interaction deficits.
Researchers created single-chain nanoparticles with thermoresponsive properties, which can be used to produce high-resolution internal images of the human body. These particles create a rich optical contrast that can be used to examine tumors more closely.
A new AI tool provides fully automated, easy-to-use evaluation of brain tumors using amino acid PET scans. The deep learning-based segmentation algorithm assesses treatment response with quality comparable to that of an experienced physician.
Cells employ a protective mechanism to preserve orphan ribosomal proteins during heat shock, allowing for rapid recovery once the stress subsides. This study uses lattice light sheet 4D imaging and pulse labeling with HaloTag dye to visualize these processes in real-time.
A team of researchers has developed a new visualization tool combining high-speed cameras and fluorescent injection to distinguish tumor tissue from normal tissue across cancer types. The technique, known as fluorescence lifetime (FLT) imaging, achieved an accuracy of over 97% in distinguishing tumor tissue from healthy tissue.
Researchers found a single dose of ADC therapy combined with lovastatin reduced tumor volume rates similar to multiple doses in preclinical settings. Immuno-PET scans also monitored HER2 tumor levels after treatment, offering real-time insights into therapy response and potential personalized cancer treatments.
A phase 2 clinical trial found that serial blood tests can identify patients who benefit from additional immunotherapies, suggesting a potential early marker of treatment response. The study also showed that ctDNA analyses correlated with tumor size and survival, making it a promising strategy for guiding therapy.
The study developed a highly accurate AI model for fully automated cancer detection, including small and difficult-to-detect tumors. The model could detect visually imperceptible cancer from normal-appearing pancreases substantially early before clinical diagnosis, with a median of 438 days.
A new tau PET radiotracer, 18F-SNFT-1, demonstrates high sensitivity and specificity in identifying Alzheimer's disease. This improved tracer enables earlier diagnosis and potential therapeutic interventions.
A new study explores how alpha-synuclein disrupts metabolic processes in neurons. Researchers used NanoSIMS imaging techniques to visualize isotopic variations and found changes in carbon turnover, suggesting increased metabolic demands on affected cells.
A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to HER2-targeted treatment in HER2-positive metastatic breast cancer patients. Whole-body PET/CT enables quantification of HER2 expression and predicts metabolic response, potentially sparing patients from unnecessary side effects.
The UCLA-led team has developed a solution to improve cryo-electron microscopy's imaging capabilities for smaller protein molecules, enabling higher-resolution images. This advance is expected to help researchers identify specific locations on proteins that can be targeted for therapeutic purposes.
A study comparing PI-RADS 2.0 and 2.1 found no significant differences in upgrade (29% vs. 22%) or downgrade (19% vs. 21%) rates from targeted biopsy to radical prostatectomy, suggesting no improvement in prostate cancer grade assessment with the latest PI-RADS update.
Researchers developed a new diffraction-gated real-time ultrahigh-speed mapping (DRUM) camera that captures dynamic events in a single exposure at 4.8 million frames per second. The camera uses off-the-shelf components and is fast enough to capture highly dynamic biomedical processes or enable high-speed lidar systems.
Micro4PAP, a fast-scan Brillouin Microscope, allows for non-destructive, label- and contact-free imaging of biological samples. The device enables sub-millisecond acquisition time, suitable for in-vivo measurements in living cells, promoting early disease detection and diagnosis.
Researchers developed a new imaging technique using Bessel beam two-photon microscopy to detect stalling in brain capillaries, which can indicate acute neurological issues. The approach generates clear images of all capillaries every two seconds, providing better temporal resolution and enabling the detection of short stalling events.
The Society of Nuclear Medicine and Molecular Imaging has issued a new consensus statement to standardize the selection and management of patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with Lu-177 PSMA radionuclide therapy. The statement recommends performing PSMA PET within three months of treatment or sin...
The research team created a multi-spectral, super-low-dose photoacoustic microscopy system with improved sensitivity, enabling new applications and clinical translation. The system achieved up to capillary-level or sub-cellular resolution at greater depths than traditional optical microscopy methods.
Imaging mass cytometry showcases odd numbers of proteins in kidneys of lupus patients, identifying novel markers for disease. The study found decreased and increased disease markers pointing to renal disease, with potential enlargement of glomeruli in some patients.
A study found that PSMA PET/CT can accurately diagnose advanced prostate cancer in elderly patients without the need for a biopsy. The procedure reduced the number of biopsies and associated complications, while providing clinical suspicion-based staging data.
Researchers at UBC Okanagan's Integrated Optics Laboratory develop imaging systems that apply terahertz radiation, enabling fast and accurate characterization of biological specimens. This technology holds promise for improving diagnostic imaging and detecting carcinogenesis.
A new imaging technique, tau PET, has been shown to predict cognitive decline in Alzheimer's patients with greater accuracy than current methods. This breakthrough could lead to earlier diagnosis and treatment, improving patient outcomes.
A new complex-domain neural network enhances large-scale coherent imaging by exploiting latent coupling information between amplitude and phase components. The technique reduces exposure time and data volume significantly while maintaining high-quality reconstructions.
Researchers developed new methods for detecting drug-induced hepatotoxicity using 3D cell cultures and mass spectrometry imaging, identifying biomarkers and effective interventions. A zeolite-based protein corona method was also used to characterize plasma proteins, enabling the identification of low-abundance proteins and their potent...
Metalenses have been developed with differentiated design principles to eliminate chromatic aberration. By merging bright spots into a single focusing spot, researchers achieved an efficiency of up to 43% and demonstrated the versatility of their approach for various optical applications.
PSMA PET imaging provides prognostic information on cancer recurrence risk before treatment, improving personalized treatments and guiding surgical plans. The tool outperforms current standard tests in predicting biochemical recurrence, a critical factor in determining cancer-specific mortality.
A novel PET perfusion radiotracer, 18F-flurpiridaz, demonstrates high diagnostic efficacy for obese patients with coronary artery disease, outperforming traditional imaging methods. The study showed improved sensitivity and specificity in diagnosing significant CAD, even at lower radiation doses.
A study using molecular imaging found that individuals with obesity respond differently to food cues than normal-weight individuals, with altered connectivity between brain networks. The research offers valuable insights into potential medical interventions for obesity, including novel drug treatments and behavioral therapies.
A newly discovered radionuclide-based agent (CB-2PA-NT) has shown high tumor uptake, sustained retention, and contrast in preclinical models. Targeting neurotensin receptors, CB-2PA-NT expands precision medicine for cancer diagnosis and treatment.
Cathy Sue Cutler is elected SNMMI president-elect to tackle talent shortages, funding issues and education gaps in the field. She aims to attract talent, enhance training opportunities and educate practitioners on theranostics for personalized medicine.
The Society of Nuclear Medicine and Molecular Imaging has recognized ten new SNMMI Fellows, including Virginia Pappas as an honorary Fellow, for their excellence in volunteer service and scientific discovery. The SNMMI Fellowship is among the most prestigious formal recognitions available to long-time members.
Dr. Peter J. H. Scott has made significant contributions to radiopharmaceutical sciences through his development of new methods and technologies. He has also received numerous awards for his research, including the Sam Gambhir Trailblazer Award.
SNMMI has elected Jean-Luc C. Urbain as Vice President-Elect, who will focus on bringing new precision oncology nuclear therapies to the clinic. He aims to implement SNMMI's strategic plan, promoting its brand globally and increasing membership and financial support.
Researchers developed a computational technique combining genomic and tau PET imaging data to identify four subtypes of Alzheimer's disease. The integrated approach also revealed top genes associated with each subtype. This personalized diagnostic technique has potential for broad utility across various diseases.
Umar Mahmood, a prominent researcher and leader in the field of nuclear medicine and molecular imaging, has been awarded the first annual SNMMI Minoshima-Pappas Transformational Leadership Award. His work focuses on developing new imaging methods for disease process examination and early therapeutic response assessment.
A study found that monitoring early-response biomarkers enables personalized dosing in prostate cancer treatment, improving patient outcomes. The approach allowed patients to take
Helen Nadel, MD, FRCPC, has been named SNMMI President, aiming to raise awareness of and access to nuclear medicine, molecular imaging, and theranostics. She will focus on precision health, standardization, diversity, and increasing qualified professionals in the field.
SNMMI-TS elects Julie Dawn Bolin as president-elect, focusing on educating students about nuclear medicine careers and improving professional development. Bolin brings extensive experience in nuclear medicine technology and education.
A new PET radiotracer called <sup> 18 </sup> F-Cholestify has been developed to visualize metabolic cholesterol clearance in the brain. The tracer successfully visualized brain cholesterol metabolism in rats, non-human primates, and humans, showing promising results for studying neurodegenerative diseases.
Mullani, a pioneer in positron emission tomography (PET) prototype development, has been recognized for his significant contributions to the field. He developed new innovations in PET designs and published the first validation of time-of-flight information in PET to improve image quality.
Dmitry Beyder has been elected as the president of the SNMMI-TS for 2023-24, aiming to increase technologists' roles in providing theranostics and nuclear medicine therapy. He brings extensive experience from various positions in the field.
Henry VanBrocklin, a professor at the University of California, San Francisco, has been recognized for his decades-long research on novel radiopharmaceuticals and their applications in medical imaging. He is being honored with the prestigious Paul C. Aebersold Award for his contributions to nuclear medicine.
Researchers have developed a new PET model to quantify cardiac amyloidosis, allowing for more accurate diagnoses and monitoring. The study found that a two-tissue reversible compartment model is the best method for quantifying 18F-flutemetamol myocardial uptake.
The global nuclear medicine initiative addresses the need for standardized educational curriculums to train physicians in nuclear theranostics procedures. The report highlights the rapid evolution of theranostic radiopharmaceuticals and emphasizes the importance of continuing medical education to maintain expertise.
A new approach uses pretherapy imaging and dosimetry to personalize radioactive iodine treatment for refractory differentiated thyroid cancer patients. The method allows researchers to calculate personalized dosage of treatment, resulting in improved outcomes.
A novel imaging agent has been developed to non-invasively detect pulmonary fibrosis in its early stages. The agent targets extracellular matrix fibers and has shown significant uptake in lungs with pulmonary fibrosis, matching histological results. This breakthrough could lead to earlier detection and better monitoring of the disease.
Researchers developed a novel endoscopic imaging system with a bioinspired sensor that can detect multiple fluorescent probes, enabling more accurate fluorescence-guided cancer surgery. The system showed improved spatial resolution and sensitivity in detecting tumors, paving the way for the adoption of multi-tracer FGS.
Researchers at the Beckman Institute for Advanced Science and Technology have developed a new framework for super-resolution ultrasound using deep learning, reducing processing speeds from minutes to seconds. The new technology enables real-time blood flow visualization, overcoming challenges faced by conventional methods.
A recent meta-analysis shows that amino acid PET can accurately differentiate between recurrent brain metastases and treatment-related changes. This technology has the potential to reduce unnecessary invasive procedures and overtreatment in patients with cancer.
Scientists have developed a new method to deliver genetic information to stem cells using nanoparticles coated with a specific polymer, enabling more efficient control over cellular differentiation. This innovation has the potential to improve the efficiency and effectiveness of regenerative medicine treatments.
A new study has shown that FAPI PET imaging is superior to standard FDG PET in evaluating multiple types of cancer. A newly designed FAP-targeted treatment also suppressed tumor growth in several common cancers, suggesting a powerful tool for the field of clinical nuclear medicine.
A new Raman probe, 9CN-JCR, has been developed for detecting multiple enzyme activities in heterogeneous biological tissues. The probe exhibits high sensitivity and multiplexing ability, making it a promising tool for cancer diagnosis and research.
A new PSMA PET scoring system, the tumor-to-salivary gland ratio (PSG score), can predict patient response to <sup> 177 </sup> Lu-PSMA therapy. Patients with high PSG scores had longer PSA progression-free survival and overall survival rates.
The Society of Nuclear Medicine and Molecular Imaging has issued new appropriate use criteria (AUC) for lymphoscintigraphy in sentinel node mapping and lymphedema/lipedema. The AUC covers four clinical categories of cancer, including breast cancer, skin cancer, and others, and addresses pediatric considerations.
A new nuclear medicine therapy has been shown to cure human non-Hodgkin lymphoma in an animal model, achieving a median survival of over 221 days. The treatment, [177Lu]Lu-ofatumumab, was found to quickly eliminate tumor cells and showed favorable in vitro characteristics.